Compile Data Set for Download or QSAR
maximum 50k data
Found 5689 with Last Name = 'vasbinder' and Initial = 'm'
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM454520(US10717746, Example 3)
Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM454521(US10717746, Example 4)
Affinity DataIC50:  3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM454525(US10717746, Example 8)
Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM50528817(CHEMBL4462530 | US10717746, Example 14 | US2023041...)
Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM454533(US10717746, Example 16)
Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM454535(US10717746, Example 18)
Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM454536(US10717746, Example 19)
Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM454536(US10717746, Example 19)
Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM454537(US10717746, Example 20)
Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM454537(US10717746, Example 20)
Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM454538(US10717746, Example 21)
Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM454538(US10717746, Example 21)
Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM454539(US10717746, Example 22)
Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM454540(US10717746, Example 23)
Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM454540(US10717746, Example 23)
Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM454541(US10717746, Example 24)
Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM454542(US10717746, Example 25 | US10717746, Example 84)
Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM454543(US10717746, Example 26)
Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM454544(US10717746, Example 27)
Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM454548(US10717746, Example 31)
Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50288437(CHEMBL4165758)
Affinity DataIC50: <3nMAssay Description:GRAC: human PDE2A selective inhibitorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50288438(CHEMBL4173676)
Affinity DataIC50: <3nMAssay Description:Inhibition of cytoplasmic recombinant human GST-tagged JAK1 (886 to 1154 residues) expressed in insect cells using FITC-C6-KKHTDDGYMPMSPGVA-NH as sub...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50288511(CHEMBL4171692)
Affinity DataIC50: <3nMAssay Description:Inhibition of cytoplasmic recombinant human GST-tagged JAK1 (886 to 1154 residues) expressed in insect cells using FITC-C6-KKHTDDGYMPMSPGVA-NH as sub...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50288439(CHEMBL4163817)
Affinity DataIC50: <3nMAssay Description:Inhibition of cytoplasmic recombinant human GST-tagged JAK1 (886 to 1154 residues) expressed in insect cells using FITC-C6-KKHTDDGYMPMSPGVA-NH as sub...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50288443(CHEMBL4166989)
Affinity DataIC50: <3nMAssay Description:Inhibition of cytoplasmic recombinant human GST-tagged JAK1 (886 to 1154 residues) expressed in insect cells using FITC-C6-KKHTDDGYMPMSPGVA-NH as sub...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase JAK1 [866-1154](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical

US Patent
LigandPNGBDBM264225((2R)-3-methoxy-N- (3-{2-[(3-methoxy- 1-methyl-1H-p...)
Affinity DataIC50: <3nMAssay Description:Enzyme inhibition studies were performed using recombinant JAK1 (amino acids 866-1154, Life Technologies, PV4774, Carlsbad, Calif.), JAK2 (amino acid...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [866-1154](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical

US Patent
LigandPNGBDBM264231((2R)-N-(3-{5-fluoro- 2-[(3-methoxy-1- methyl-1H-py...)
Affinity DataIC50: <3nMAssay Description:Enzyme inhibition studies were performed using recombinant JAK1 (amino acids 866-1154, Life Technologies, PV4774, Carlsbad, Calif.), JAK2 (amino acid...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [866-1154](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical

US Patent
LigandPNGBDBM264233((2R)-N-(3-{2- [(1,3-dimethyl-1H- pyrazol-4-yl)amin...)
Affinity DataIC50: <3nMAssay Description:Enzyme inhibition studies were performed using recombinant JAK1 (amino acids 866-1154, Life Technologies, PV4774, Carlsbad, Calif.), JAK2 (amino acid...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [866-1154](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical

US Patent
LigandPNGBDBM264225((2R)-3-methoxy-N- (3-{2-[(3-methoxy- 1-methyl-1H-p...)
Affinity DataIC50: <3nMAssay Description:Enzyme inhibition studies were performed using recombinant JAK1 (amino acids 866-1154, Life Technologies, #PV4774, Carlsbad, Calif.), JAK2 (amino aci...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [866-1154](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical

US Patent
LigandPNGBDBM264231((2R)-N-(3-{5-fluoro- 2-[(3-methoxy-1- methyl-1H-py...)
Affinity DataIC50: <3nMAssay Description:Enzyme inhibition studies were performed using recombinant JAK1 (amino acids 866-1154, Life Technologies, #PV4774, Carlsbad, Calif.), JAK2 (amino aci...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [866-1154](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical

US Patent
LigandPNGBDBM264233((2R)-N-(3-{2- [(1,3-dimethyl-1H- pyrazol-4-yl)amin...)
Affinity DataIC50: <3nMAssay Description:Enzyme inhibition studies were performed using recombinant JAK1 (amino acids 866-1154, Life Technologies, #PV4774, Carlsbad, Calif.), JAK2 (amino aci...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50288372(CHEMBL4173429)
Affinity DataIC50: <3nMAssay Description:Inhibition of cytoplasmic recombinant human GST-tagged JAK1 (886 to 1154 residues) expressed in insect cells using FITC-C6-KKHTDDGYMPMSPGVA-NH as sub...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50288378(CHEMBL4162065)
Affinity DataIC50: <3nMAssay Description:GRAC: human IMPase 1 inhibitorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase JAK1 [866-1154](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical

US Patent
LigandPNGBDBM264225((2R)-3-methoxy-N- (3-{2-[(3-methoxy- 1-methyl-1H-p...)
Affinity DataIC50: <3nMpH: 7.3Assay Description:Enzyme inhibition studies were performed using recombinant JAK1 (amino acids 866-1154, Life Technologies, #PV4774, Carlsbad, Calif.), JAK2 (amino aci...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [866-1154](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical

US Patent
LigandPNGBDBM264231((2R)-N-(3-{5-fluoro- 2-[(3-methoxy-1- methyl-1H-py...)
Affinity DataIC50: <3nMpH: 7.3Assay Description:Enzyme inhibition studies were performed using recombinant JAK1 (amino acids 866-1154, Life Technologies, #PV4774, Carlsbad, Calif.), JAK2 (amino aci...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [866-1154](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical

US Patent
LigandPNGBDBM264233((2R)-N-(3-{2- [(1,3-dimethyl-1H- pyrazol-4-yl)amin...)
Affinity DataIC50: <3nMpH: 7.3Assay Description:Enzyme inhibition studies were performed using recombinant JAK1 (amino acids 866-1154, Life Technologies, #PV4774, Carlsbad, Calif.), JAK2 (amino aci...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Astrazeneca R&D Boston

Curated by ChEMBL
LigandPNGBDBM50243624((R)-1-(3-(azepan-3-ylcarbamoyl)-5-phenylthiophen-2...)
Affinity DataIC50:  3nMAssay Description:Inhibition of Chk1More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Astrazeneca R&D Boston

Curated by ChEMBL
LigandPNGBDBM50243148(1-(3-((S)-piperidin-3-ylcarbamoyl)-5-(thiophen-2-y...)
Affinity DataIC50:  3nMAssay Description:Inhibition of Chk1More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM50588266(CHEMBL5181709)
Affinity DataIC50: <3nMAssay Description:Inhibition of CDK9 (unknown origin) using FITC-X-GSRTPMY-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM50588290(CHEMBL5191725)
Affinity DataIC50: <3nMAssay Description:Inhibition of CDK9 (unknown origin) using FITC-X-GSRTPMY-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM50588255(CHEMBL5170195)
Affinity DataIC50: <3nMAssay Description:Inhibition of CDK9 (unknown origin) using FITC-X-GSRTPMY-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM167534(US9073922, 18 | US9796708, Example 18)
Affinity DataIC50: <3nMAssay Description:Inhibition of CDK9 (unknown origin) using FITC-X-GSRTPMY-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after ...More data for this Ligand-Target Pair
In DepthDetails PubMed
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM50588261(CHEMBL5170524)
Affinity DataIC50: <3nMAssay Description:Inhibition of CDK9 (unknown origin) using FITC-X-GSRTPMY-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM50588262(CHEMBL5197170)
Affinity DataIC50: <3nMAssay Description:Inhibition of CDK9 (unknown origin) using FITC-X-GSRTPMY-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after ...More data for this Ligand-Target Pair
In DepthDetails PubMed
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM50588263(CHEMBL5198038)
Affinity DataIC50: <3nMAssay Description:Inhibition of CDK9 (unknown origin) using FITC-X-GSRTPMY-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM50588264(CHEMBL5207871)
Affinity DataIC50: <3nMAssay Description:Inhibition of CDK9 (unknown origin) using FITC-X-GSRTPMY-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM50588263(CHEMBL5198038)
Affinity DataIC50: <3nMAssay Description:Inhibition of CDK9 (unknown origin) using FITC-X-GSRTPMY-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM50588272(CHEMBL5180640)
Affinity DataIC50: <3nMAssay Description:Inhibition of CDK9 (unknown origin) using FITC-X-GSRTPMY-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetTyrosine-protein kinase JAK1 [866-1154](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical

US Patent
LigandPNGBDBM264225((2R)-3-methoxy-N- (3-{2-[(3-methoxy- 1-methyl-1H-p...)
Affinity DataIC50: <3nMAssay Description:Enzyme inhibition studies were performed using recombinant JAK1 (amino acids 866-1154, Life Technologies, #PV4774, Carlsbad, Calif.), JAK2 (amino aci...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [866-1154](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical

US Patent
LigandPNGBDBM264231((2R)-N-(3-{5-fluoro- 2-[(3-methoxy-1- methyl-1H-py...)
Affinity DataIC50: <3nMAssay Description:Enzyme inhibition studies were performed using recombinant JAK1 (amino acids 866-1154, Life Technologies, #PV4774, Carlsbad, Calif.), JAK2 (amino aci...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 5689 total ) | Next | Last >>
Jump to: